Background Multi-organ disease with cardiac involvement carries a very poor prognosis in Systemic AL Amyloidosis. The risk of nephrogenic systemic fibrosis is a significant obstacle in assessing cardiac status using CMR in patients with systemic AL amyloidosis who have advanced renal failure. Measurement of myocardial T1 values has been limited until now, due to long breathhold times. We have d...

Systemic sclerosis (SSc) is a fibrosing connective tissue disease with significantly increased mortality. Therapeutic options to treat fibrosis are limited. The small molecule tyrosine kinase inhibitor imatinib and related drugs such as dasatinib and nilotinib target simultaneously two of the major profibrotic pathways, TGFbeta- and PDGF- signaling. Imatinib, dasatinib and nilotinib inhibit col...

Purpose: Higher doses of gadolinium-based contrast agents (GBCA) are often used for contrast-enhanced MRA (CE-MRA). Patients with moderateto-severe (stages 3-5) chronic kidney disease undergoing contrast-enhanced MR imaging are known to be at increased risk for developing nephrogenic systemic fibrosis, particularly with higher doses or repeated exposure to GBCA (1-2). Herein we review informati...